These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36267741)

  • 1. Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.
    Yu W; Zhang H; Chen J; Zhang X; Chen Y; Qu G; Huang G; Zhou Y; Ye T; Fan Z; Yao Y
    Ann Transl Med; 2022 Sep; 10(18):981. PubMed ID: 36267741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.
    Wang X; Wang J; Sun B; Sun Y; Liu N; Niu X; Li C; Li L; Zhang Q; Hao J; Wang X
    Ann Transl Med; 2022 Sep; 10(18):961. PubMed ID: 36267758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study.
    Ren Y; Wang T; Cheng X; Ke G; Huang Y; Yang H; Huang X; Tian W; Wang H
    Ann Transl Med; 2023 Jan; 11(2):106. PubMed ID: 36819505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
    Liu X; Xu J; Li F; Liao Z; Ren Z; Zhu L; Shi Y; Zhao G; Bai X; Zhao J; Xing R; Teng S; Yang Y; Yang J
    Biomed Pharmacother; 2020 Feb; 122():109587. PubMed ID: 31786466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
    Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
    Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
    Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
    Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
    Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution.
    Wang Y; Lu M; Zhou Y; Zhou S; Yu X; Tang F; Luo Y; Zhang W; Duan H; Min L; Tu C
    Cancer Manag Res; 2020; 12():5255-5264. PubMed ID: 32669874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
    Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
    Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
    Zhang G; Gong S; Pang L; Hou L; He W
    Front Oncol; 2021; 11():659217. PubMed ID: 34012920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
    Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
    Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
    Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
    [No Abstract]   [Full Text] [Related]  

  • 14. Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study.
    Wang C; Huang M; Geng Q; Li W; Chang J; Tang W; Guo W
    Ther Adv Med Oncol; 2021; 13():17588359211039047. PubMed ID: 34484431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study.
    Zhao S; Fan N; Li H; Liu J; Huang F; Chen Y; Zhou M; Yu J; Lin R
    Ann Transl Med; 2020 Oct; 8(19):1233. PubMed ID: 33178765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution.
    Wang Y; Min L; Zhou Y; Tang F; Luo Y; Zhang W; Duan H; Tu C
    Cancer Manag Res; 2019; 11():3583-3591. PubMed ID: 31118781
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
    Weitao Y; Fangxing W; Qiqing C; Jiaqiang W
    Anticancer Drugs; 2019 Aug; 30(7):e0778. PubMed ID: 31305297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study.
    Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Gao S; Liu O; Yao W
    Front Oncol; 2023; 13():1124517. PubMed ID: 36910639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Fruquintinib-Based Treatment in Patients with Refractory Bone and Soft Tissue Sarcoma after Developing Resistance to Several TKIs: A Multicenter Retrospective Study.
    Yang C; Li B; Dong S; Xu J; Sun X; Liang X; Liu K; Sun K; Yang Y; Ji T; Ye Z; Xie L; Tang X
    Orthop Surg; 2024 Oct; 16(10):2380-2390. PubMed ID: 39030807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
    Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
    Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.